Results 131 to 140 of about 6,357,689 (285)
special reduced fare information great service . . . great low fares [PDF]
openalex +1 more source
Cytokine, Chemokine, and Neurofilament Light Chain Signatures in LGI1 Autoimmune Encephalitis
ABSTRACT Objectives To investigate the value of cytokine, chemokine, and neurofilament light chain (NfL) concentrations in predicting relapse risk, chronic epilepsy, and functional impairment in LGI1 autoimmune encephalitis (AE). Methods Cytokines/chemokines (IL‐1‐beta, IL‐2, IL‐4, IL‐5, IL‐6, IL‐8/CXCL8, IL‐10, IL‐12p70, IL‐13, IL‐17A, GM‐CSF, TNF ...
Albert Aboseif+17 more
wiley +1 more source
PUBLIC AFFAIRS REPORT: compiled by the Information Services Staff of the Executive Office [PDF]
openalex +1 more source
Communications and media services [PDF]
NASA's internal and external communication methods are reviewed. NASA information services for the media, for the public, and for employees are discussed.
Kukowski, James F., Mcculla, James W.
core +1 more source
Long‐Term Evaluation of Givinostat in Duchenne Muscular Dystrophy, and Natural History Comparisons
ABSTRACT Objectives This ongoing, open‐label extension study is evaluating the long‐term safety, tolerability, and efficacy of givinostat, a Class I and II histone deacetylase inhibitor, in patients with Duchenne muscular dystrophy (DMD). Methods The recruited patients completed one of two prior clinical studies (one Phase 2 and one Phase 3 [EPIDYS ...
Craig M. McDonald+74 more
wiley +1 more source
INFORMATION AND COMMUNICATION TECHNOLOGIES (ICTs) IN THE SERVICES OF HEALTHCARE SECTOR IN EUROPE [PDF]
Information and Communication Technologies (ICTs) consists of all technical means used to handle information and aid communication, including both computer and network hardware as well as necessary software.
Pavel (El Baaboua) Florentina Ramona
core
The Library and Information Service [PDF]
Susan Floate+3 more
openaire +3 more sources
Durability of Response to B‐Cell Maturation Antigen‐Directed mRNA Cell Therapy in Myasthenia Gravis
ABSTRACT Objective We report the 12‐month follow‐up outcomes from a Phase 2 clinical trial (NCT04146051) evaluating Descartes‐08, a BCMA‐directed RNA chimeric antigen receptor T‐cell (rCAR‐T) therapy for refractory generalized myasthenia gravis (MG).
Nizar Chahin+10 more
wiley +1 more source
Policies on developing the scientific and technical information service
T Nagano
openalex +2 more sources